Publication:

Which one is the best-comparison of three treatment modalities in membranous glomerulonephropathy?

Background This retrospective study explores the efficacy of Modified Ponticelli, Rituximab and Tacrolimus in treating membranous nephropathy, focusing on remission rates.

Methods This retrospective study analyzed 41 membranous nephropathy cases treated with Modified Ponticelli, Rituximab, or Tacrolimus. Statistical analyses included Kruskal-Wallis and Chi-Square tests to evaluate treatment responses, renal markers and remission outcomes, providing comprehensive insights into treatment efficacy.

Results Modified Ponticelli demonstrated substantial reductions in proteinuria (-88.20%) and favorable increases in albumin (15.80%), outperforming Rituximab and Tacrolimus. Significant differences (p=0.0014) in remission outcomes underscore Modified Ponticelli's efficacy, with the highest complete remission rate (26.7%) and notable partial remission rate (73.3%). Rituximab (Complete 0%, Partial 46.2%) and Tacrolimus (Complete 15.4%, Partial 30.8%) exhibited lower rates.

Conclusions In conclusion, Modified Ponticelli demonstrates superior efficacy in achieving both complete and partial remission in membranous nephropathy patients.